Earlier this month (June 5, 2026), the European Society for Medical Oncology (ESMO) joined the World Health Organization's Global Clinical Trials Forum, "reinforcing its long-standing collaboration...to advancing more equitable, high-quality clinical research worldwide." This new partnership further strengthens the mission of ESMO to provide equal access to best possible treatments for cancer patients worldwide.
Click here to read more.
A stronger global trials ecosystem matters most for patients outside major academic centres, where trial access is often decided by geography rather than need. Aligning standards and sharing infrastructure could shorten the gap between a promising result and its availability in community practice. The two onc docs show notes are a good example of how trial updates get translated into practical takeaways for clinicians who cannot follow every international forum directly.
ReplyDeleteESMO joining WHO's Global Clinical Trials Forum feels like a natural next step — equitable trial access has been the bottleneck in making breakthroughs actually matter worldwide. Aligning standards and sharing infrastructure across borders could do more for global survival rates than any single drug. It will be interesting to see how quickly this partnership turns into concrete trial-site support in lower-resource settings.
ReplyDelete